<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103295</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-P2-14</org_study_id>
    <nct_id>NCT03103295</nct_id>
  </id_info>
  <brief_title>3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects</brief_title>
  <acronym>3-D-TEBE</acronym>
  <official_title>Safety and Efficacy Study of Traumatic Bone Defects Treatment With Use of 3D Tissue Engineered Equivalent.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.A. Partners, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A.A. Partners, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates safety and efficacy of traumatic bone defects treatment with use of&#xD;
      3D tissue engineered bone equivalent (3D-TEBE).&#xD;
&#xD;
      The aim of this study is to evaluate 3D-TEBE transplantation as a safe and efficient&#xD;
      treatment for patients with traumatic long bone defects of critical size.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This new method of critical sized long bone defects treatment is under clinical development.&#xD;
      Treatment of critical sized bone defects is an actual clinical challenge. The &quot;gold standard&quot;&#xD;
      in this case is autologous bone grafting. The method disadvantage is associated with limited&#xD;
      donor bone resources. Based on our preliminary clinical trial positive results on use of&#xD;
      autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs) in&#xD;
      traumatology, our aim was to develop 3D tissue-engineered bone equivalent transplantation&#xD;
      technology for restoration of critical sized bone defects. The proposed 3D-TEBE&#xD;
      transplantation for bone defects of critical size treatment expecting to restore the bone&#xD;
      integrity, form new bone tissue in a site of bone defect, and reduce the rehabilitation&#xD;
      period of a patient.&#xD;
&#xD;
      The data obtained from this study will have practical implications for the treatment of&#xD;
      reparative osteogenesis alterations and will be based on the principles of evidence-based&#xD;
      medicine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">November 20, 2015</start_date>
  <completion_date type="Anticipated">December 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic and MRI assessment in progression</measure>
    <time_frame>12 months +3 years following 3D Tissue Engineered Bone Equivalent grafting</time_frame>
    <description>Radiological and MRI progression of consolidation of bone fragments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain using VAS</measure>
    <time_frame>6 months</time_frame>
    <description>Patients feel less pain during use of fractured limb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis based on length of hospital stay</measure>
    <time_frame>6 months</time_frame>
    <description>Cost benefit of 3D-TEBE transplantation by reduction of hospital admission time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bone Defects</condition>
  <arm_group>
    <arm_group_label>3D-Tissue Engineered Bone Equivalent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with bone defects of critical size of long bones&#xD;
3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3D-Tissue Engineered Bone Equivalent</intervention_name>
    <description>Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent</description>
    <arm_group_label>3D-Tissue Engineered Bone Equivalent</arm_group_label>
    <other_name>Tissue-engineered bone-like construct transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 60 years&#xD;
&#xD;
          -  Patients with long bone defects of critical size of the traumatic genesis;&#xD;
&#xD;
          -  Lack of consolidation of bone fragments for at least 9 months;&#xD;
&#xD;
          -  At least two attempts to achieve bone consolidation using traditional methods of&#xD;
             treatment;&#xD;
&#xD;
          -  A negative pregnancy test at women of childbearing age;&#xD;
&#xD;
          -  Confirmation of participation in the study by signing The Written Informed Consent,&#xD;
             personally or through a responsible caretaker;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The infection in the area of bone defect;&#xD;
&#xD;
          -  History of prior cancer;&#xD;
&#xD;
          -  Diabetes;&#xD;
&#xD;
          -  Severe chronic liver diseases or kidneys disease in history&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  The presence of vascular, endocrine and somatic pathology which has a direct impact on&#xD;
             the osteoreparation;&#xD;
&#xD;
          -  Any other physical diseases in decompensation or subcompensation, or those that are&#xD;
             rated as severe or moderate;&#xD;
&#xD;
          -  Therapeutic issues or psychiatric disorders of a patient which would make the subject&#xD;
             unsuitable to participate in this study or to complete it;&#xD;
&#xD;
          -  Participation in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volodymyr M. Oksymets, MD,PhD,DSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>LIMITED LIABILITY COMPANY &quot;A.A. PARTNERS&quot; (Medical company ilaya® ),</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LIMITED LIABILITY COMPANY &quot;A.A. PARTNERS&quot; (Medical company ilaya®)</name>
      <address>
        <city>Kiev</city>
        <zip>03115, 9, I. Kramskogo Str.</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://ecmjournal.org/journal/supplements/vol031supp01/pdf_posters/Vol031Supp01P410.pdf</url>
    <description>RG Vasyliev, DO Zubov, AE Rodnichenko, OS Gubar, AV Zlatska, VM Oksymets. Bone tissue engineering for critical sized bone defects// European Cells and Materials Vol. 31. Suppl. 1, 2016. - Page P410</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tissue engineering,</keyword>
  <keyword>regeneration,</keyword>
  <keyword>repair,</keyword>
  <keyword>traumatic bone defects,</keyword>
  <keyword>regenerative therapy</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

